Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Acalabrutinib Plus Obinutuzumab in Untreated Indolent Non-Hodgkin Lymphomas
NCT04883437Phase 2Recruiting
- Sponsor
- Emory University
- Start
- Sep 2021
- Primary completion
- Sep 2026
- Countries
- 1
01
Overview
A Phase 2 trial of acalabrutinib tablet (Variant 1) in follicular lymphoma (FL), non-Hodgkin lymphoma (NHL), Lymphoplasmacytic Lymphoma (LPL), mantle cell lymphoma (MCL), marginal zone lymphoma (MZL), sponsored by Emory University. Started Sep 2021; status: recruiting.
02
Drugs
acalabrutinib tablet (Variant 1)
03
Conditions
follicular lymphoma (FL)non-Hodgkin lymphoma (NHL)Lymphoplasmacytic Lymphoma (LPL)mantle cell lymphoma (MCL)marginal zone lymphoma (MZL)
Beyond the preview
Go deeper on NCT04883437.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04883437.